In lung adenocarcinomas, 2–4% present activating mutations within the kinase domain of ERBB2 analogous to those detected in EGFR and never coexisting with EGFR, KRAS, or ALK alterations (3–5). The gene discussed is EGFR; the disease is lung adenocarcinoma.